Pharmacovigilance in Africa

Alexander N.O. Dodoo; Haggar H. Ampadu

doi:10.1002/9781118820186.ch17

Pharmacovigilance in Africa

Alexander N.O. Dodoo, Haggar H. Ampadu

Centre for Tropical, Clinical Pharmacology & Therapeutics

University of Ghana

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

3 Citations (Scopus)

Abstract

The last 20 years have seen seismic shifts in the political, civil, and healthcare environment in Africa. Currently, 33 national pharmacovigilance (PV) centers in Africa are full members of the WHO Programme for International Drug Monitoring, whilst another six are associate members. A recent analysis showed that the challenges facing African PV centers include the lack of human and financial resources. The total number of spontaneous reports from African countries is extremely low even for drugs that are used heavily within the region. Despite this low reporting, a safety signal - that is, extrapyramidal reactions with the antimalarial drug combination of amodiaquine + artesunate - has been generated entirely due to PV efforts in Africa. PV in Africa is evolving, and key stakeholders like the pharmaceutical industry are being brought on board. Indicators for PV exist (Strengthening Pharmaceutical Systems (SPS) Program, 2009) or are being developed.

Original language	English
Title of host publication	Mann's Pharmacovigilance
Subtitle of host publication	Third Edition
Publisher	Wiley Blackwell
Pages	299-301
Number of pages	3
ISBN (Electronic)	9781118820186
ISBN (Print)	9780470671047
DOIs	https://doi.org/10.1002/9781118820186.ch17
Publication status	Published - 23 Jun 2014

Keywords

Adverse drug reactions (ADRs)
Africa
Pharmacovigilance (PV)
Strengthening PharmacovigilanceSystems (SPS) Program

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/9781118820186.ch17

Cite this

@inbook{72fb3a8b74814ac2a6d70e903cb8387c,

title = "Pharmacovigilance in Africa",

abstract = "The last 20 years have seen seismic shifts in the political, civil, and healthcare environment in Africa. Currently, 33 national pharmacovigilance (PV) centers in Africa are full members of the WHO Programme for International Drug Monitoring, whilst another six are associate members. A recent analysis showed that the challenges facing African PV centers include the lack of human and financial resources. The total number of spontaneous reports from African countries is extremely low even for drugs that are used heavily within the region. Despite this low reporting, a safety signal - that is, extrapyramidal reactions with the antimalarial drug combination of amodiaquine + artesunate - has been generated entirely due to PV efforts in Africa. PV in Africa is evolving, and key stakeholders like the pharmaceutical industry are being brought on board. Indicators for PV exist (Strengthening Pharmaceutical Systems (SPS) Program, 2009) or are being developed.",

keywords = "Adverse drug reactions (ADRs), Africa, Pharmacovigilance (PV), Strengthening PharmacovigilanceSystems (SPS) Program",

author = "Dodoo, {Alexander N.O.} and Ampadu, {Haggar H.}",

year = "2014",

month = jun,

day = "23",

doi = "10.1002/9781118820186.ch17",

language = "English",

isbn = "9780470671047",

pages = "299--301",

booktitle = "Mann's Pharmacovigilance",

publisher = "Wiley Blackwell",

}

TY - CHAP

T1 - Pharmacovigilance in Africa

AU - Dodoo, Alexander N.O.

AU - Ampadu, Haggar H.

PY - 2014/6/23

Y1 - 2014/6/23

N2 - The last 20 years have seen seismic shifts in the political, civil, and healthcare environment in Africa. Currently, 33 national pharmacovigilance (PV) centers in Africa are full members of the WHO Programme for International Drug Monitoring, whilst another six are associate members. A recent analysis showed that the challenges facing African PV centers include the lack of human and financial resources. The total number of spontaneous reports from African countries is extremely low even for drugs that are used heavily within the region. Despite this low reporting, a safety signal - that is, extrapyramidal reactions with the antimalarial drug combination of amodiaquine + artesunate - has been generated entirely due to PV efforts in Africa. PV in Africa is evolving, and key stakeholders like the pharmaceutical industry are being brought on board. Indicators for PV exist (Strengthening Pharmaceutical Systems (SPS) Program, 2009) or are being developed.

AB - The last 20 years have seen seismic shifts in the political, civil, and healthcare environment in Africa. Currently, 33 national pharmacovigilance (PV) centers in Africa are full members of the WHO Programme for International Drug Monitoring, whilst another six are associate members. A recent analysis showed that the challenges facing African PV centers include the lack of human and financial resources. The total number of spontaneous reports from African countries is extremely low even for drugs that are used heavily within the region. Despite this low reporting, a safety signal - that is, extrapyramidal reactions with the antimalarial drug combination of amodiaquine + artesunate - has been generated entirely due to PV efforts in Africa. PV in Africa is evolving, and key stakeholders like the pharmaceutical industry are being brought on board. Indicators for PV exist (Strengthening Pharmaceutical Systems (SPS) Program, 2009) or are being developed.

KW - Adverse drug reactions (ADRs)

KW - Africa

KW - Pharmacovigilance (PV)

KW - Strengthening PharmacovigilanceSystems (SPS) Program

UR - http://www.scopus.com/inward/record.url?scp=84926512922&partnerID=8YFLogxK

U2 - 10.1002/9781118820186.ch17

DO - 10.1002/9781118820186.ch17

M3 - Chapter

AN - SCOPUS:84926512922

SN - 9780470671047

SP - 299

EP - 301

BT - Mann's Pharmacovigilance

PB - Wiley Blackwell

ER -

Pharmacovigilance in Africa

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this